story of the week
Remission Induction vs Immediate Allogeneic HSCT for Relapsed or Poorly Responsive AML
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial
Lancet Haematol 2024 Apr 04;[EPub Ahead of Print], M Stelljes, JM Middeke, G Bug, EM Wagner-Drouet, LP Müller, C Schmid, SW Krause, W Bethge, E Jost, U Platzbecker, SA Klein, J Schubert, J Niederland, M Kaufmann, K Schäfer-Eckart, M Schaich, H Baldauf, F Stölzel, C Petzold, C Röllig, N Alakel, B Steffen, B Hauptrock, C Schliemann, K Sockel, F Lang, O Kriege, J Schaffrath, C Reicherts, WE Berdel, H Serve, G Ehninger, AH Schmidt, M Bornhäuser, JH Mikesch, J ScheteligFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.